s6y ACURA PHARMACEUTICALS, INC 10-K

ACURA PHARMACEUTICALS, INC 10-K, filed Jun 7, 2018: IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2017
Accounting Policies [Abstract]  
Non-Cash Share-Based Compensation Expense
Our share-based compensation expense recognized in the Company’s results of operations from all types of noncash and cash-portioned instruments issued comprised the following (in thousands):
 
 
 
Year Ended 
December 31,
 
 
 
2017
 
2016
 
Research and development expense:
 
 
 
 
 
 
 
Stock option awards
 
$
136
 
$
167
 
RSU awards
 
 
3
 
 
-
 
 
 
$
139
 
$
167
 
 
 
 
 
 
 
 
 
Selling, marketing, general and administrative expense:
 
 
 
 
 
 
 
Stock option awards
 
 
203
 
 
301
 
RSU awards
 
 
156
 
 
143
 
 
 
$
359
 
$
444
 
 
 
 
 
 
 
 
 
Total share-based compensation expense
 
$
498
 
$
611
 
Estimated Lives of Major Classification of Depreciable Assets
The estimated useful lives of the major classification of depreciable assets are:
 
Building and improvements
10 - 40 years
Land and improvements
20 - 40 years
Machinery and equipment
7 - 10 years
Scientific equipment
5 - 10 years
Computer hardware and software
3 - 10 years
Concentration of Risk, by Risk Factor
Sales to certain of our customers during 2016 accounting for 10% or more of our annual product sales, whether the product shipment was recognized immediately as a sales or as a deferred sale, is presented below.
 
Customer
 
2016
 
Rite Aid Corporation
 
 
55
%
Cardinal Health, Inc.
 
 
13
%
McKesson Corporation
 
 
10
%
 
 
 
 
 
Trade accounts receivable from certain of our customers at December 31, 2016 accounting for 10% or more of our gross accounts receivable is presented below.
 
Customer
 
2016
 
AmerisourceBergen Corporation
 
 
35
%
McKesson Corporation
 
 
24
%
Cardinal Health, Inc.
 
 
19
%
The Kroger Co.
 
 
18
%
Rite Aid Corporation
 
 
**